Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Expanded Access for Apixaban

  • Read more about Expanded Access for Apixaban

Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

  • Read more about Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

ILiAD Biotechnologies

By efain on Thu, 02/24/2022 - 13:19
  • Read more about ILiAD Biotechnologies

Immunic

By efain on Thu, 02/24/2022 - 13:14
  • Read more about Immunic

Poxel

By efain on Thu, 02/24/2022 - 13:03
  • Read more about Poxel

Lion TCR

By efain on Thu, 02/24/2022 - 12:55
  • Read more about Lion TCR

Dizal Pharmaceutical Co., Ltd

By efain on Thu, 02/24/2022 - 12:50
  • Read more about Dizal Pharmaceutical Co., Ltd

Myeloid Therapeutics

By efain on Thu, 02/24/2022 - 12:45
  • Read more about Myeloid Therapeutics

Substance Use Disorders

Learn how the Reagan-Udall Foundation for the FDA supports strategies to prevent, treat, and manage substance use disorders by engaging stakeholders and addressing critical gaps in the SUD treatment system.
  • Read more about Substance Use Disorders

Vivoryon Therapeutics NV

By efain on Thu, 01/06/2022 - 16:39
  • Read more about Vivoryon Therapeutics NV

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 157
  • Page 158
  • Page 159
  • Page 160
  • Current page 161
  • Page 162
  • Page 163
  • Page 164
  • Page 165
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA